Cystic Fibrosis Market in Europe 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profiles
05.1.1 Zenpep
05.1.2 Colomycin/Colobreathe
05.1.3 Pulmozyme
05.1.4 Cayston
05.1.5 TOBI/TOBI Podhaler
05.1.6 Kalydeco
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Pathophysiology
07.3 Epidemiology
07.3.1 Global
07.3.2 UK
07.4 Diagnosis
07.4.1 Carrier Testing
07.4.2 Antenatal Testing
07.4.3 Newborn Screening
07.4.4 Other Tests
07.5 Manifestations of Cystic Fibrosis
07.6 Economic Burden
08. Pipeline Portfolio
09. Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis
10. Segmentation of Cystic Fibrosis Market in Europe by Molecule Type
10.1 Biologics
10.1.1 Enzymes
10.2 Small Molecules
10.2.1 CFTR Modulators
10.2.2 Antibiotics
11. Segmentation of Cystic Fibrosis Market in Europe by Route of Administration
11.1 Oral
11.2 Parenteral
11.3 Topical
12. Segmentation of Cystic Fibrosis Market in Europe by Dosage Form
12.1 Solid
12.2 Liquid
13. Key Leading Countries
13.1 UK
13.2 France
13.3 Italy
13.4 Germany
13.5 Spain
14. Buying Criteria
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Actavis
21.2.2 F. Hoffmann-La Roche
21.2.3 Gilead Sciences
21.2.4 Novartis
21.2.5 Vertex Pharmaceuticals
21.3 Other and Future Prominent Vendors
22. Key Vendor Analysis
22.1 Actavis
22.1.1 Key Facts
22.1.2 Business Description
22.1.3 Business Segmentation
22.1.4 Business Segmentation by Revenue 2012 and 2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Information
22.1.8 SWOT Analysis
22.2 F. Hoffmann-La Roche
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation
22.2.4 Business Segmentation by Revenue 2012 and 2013
22.2.5 Sales by Geography
22.2.6 Business Strategy
22.2.7 Key Information
22.2.8 SWOT Analysis
22.3 Gilead Sciences
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Geographical Segmentation by Revenue 2013
22.3.4 Recent Developments
22.3.5 SWOT Analysis
22.4 Novartis
22.4.1 Key Facts
22.4.2 Business Description
22.4.3 Business Segmentation
22.4.4 Revenue by Business Segmentation
22.4.5 Revenue Comparison 2012 and 2013
22.4.6 Sales by Geography
22.4.7 Business Strategy
22.4.8 Key Developments
22.4.9 SWOT Analysis
22.5 Vertex Pharmaceuticals
22.5.1 Key Facts
22.5.2 Business Overview
22.5.3 Business Segmentation by Revenue 2013
22.5.4 Business Segmentation by Revenue 2012 and 2013
22.5.5 Geographical Segmentation by Revenue 2013
22.5.6 Business Strategy
22.5.7 Recent Developments
22.5.8 SWOT Analysis
23. Other Reports in this Series